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Abstract 
Background: HIV infection and opportunistic infections cause oxidative stress (OS), which is associated with tissue damage. Anti-retroviral 
therapy (ART) is used to treat HIV and decrease the risk of  opportunistic infections, but it is unclear whether ART reduces OS.  Association 
of  ART with OS was investigated.
Methods: We stratified a convenience sample of  frozen serum or plasma from HIV-infected, ART-naïve (n=21); HIV-infected, ART-treat-
ed (n=14); HIV and PTB co-infected, ART-naïve (n=21); HIV and PTB co-infected, ART-treated (n=25) patients. Controls (n=21) were 
HIV-negative adults without TB symptoms. Concentration of  OS markers namely: transaminases (ALT and AST), gamma glutamyl transpep-
tidase (GGT), albumin, total protein, malondialdehyde (MDA), vitamin C, and total anti-oxidant status (TAS) were determined.
Results: AST (p<0.001), GGT (p<0.001), total protein (p=0.001) and MDA (p<0.001) were higher in HIV patients compared to controls. 
Vitamin C (P<0.0001) and albumin (p<0.01) were lower in HIV-patients relative to controls. ART was only associated with higher albumin 
(p=0.001), higher GGT (p=0.02) and lower vitamin C (p=0.009). HIV and PTB co-infection was only significantly associated with higher 
GGT (p=0.01) and AST (p=0.03).
Conclusion: We identified severe OS among HIV-patients. ART was associated with both increased and reduced markers of  OS hence sug-
gesting that ART may not attenuate OS.
Keywords: Human immunodeficiency virus, Mycobacterium tuberculosis, Oxidative stress, anti-retroviral therapy, hospitalized patients.
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Introduction 
Human immunodeficiency virus (HIV) and tuberculosis 
(TB) are the leading infectious causes of  death world-
wide1. Globally, about 1.2 million people died from HIV 
in 2014. Of  these, 400,000 were co-infected with TB2. 
The burden of  infections is highest in sub-Saharan Africa 
where over 74% of  the world’s HIV and TB co-infections 
occur3. In 2016, about 1.4 million Ugandans were report-
ed to have HIV, and 28,000 people died of  AIDS1.
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Oxidative stress (OS) is defined as a disturbance in the 
balance between the production of  reactive oxygen spe-
cies (i.e., free radicals) and anti-oxidant defenses. HIV 
infection is associated with increased production of  
free radicals leading to OS through a number of  mech-
anisms4. HIV infection is also associated with suppres-
sion of  the anti-oxidant defense system5,6. M. tuberculosis 
(Mtb) is the leading opportunistic infection among HIV 
patients and is also associated with OS. Mtb activates 
membrane-bound NADPH-oxidase, which leads to ac-
cumulation of  reactive oxygen species7,8, leading to the 
respiratory burst and, subsequently, OS. OS predisposes 
to intracellular defects such as DNA damage leading to 
malignancies; accelerated apoptosis leading to metabol-
ic disorders and premature ageing; neurological damage 
leading to dementia; increased HIV replication leading to 
immune dysfunction9-12, and poor treatment outcomes. 
OS also predicts mortality in HIV-infected patients13.
The use of  ART has converted HIV into a chronic and 
manageable disease. It has reduced mortality and cases 
of  opportunistic infections among HIV-infected patients. 
The role of  OS in modulating HIV infection is well-es-
tablished11, but how ART modifies OS remains unclear.. 
While one study reported that ART was associated with 
decreased OS14, others found that it was associated with 
increased OS15-17. Uganda is among the 30 high TB bur-
den countries with adult HIV prevalence rate of  6.51, yet 
there is a paucity of  data regarding oxidative stress among 
HIV and TB-co-infected patients.
Uncertainity regarding the role of  ART in OS limits rec-
ommendations to intervene with anti-oxidant(s) supple-
ments to avert OS in HIV-infected patients. Thus, better 
understanding of  the role of  ART on OS may lead to 
interventions to improve outcomes. 
In this study, we aimed to: (1) compare OS markers in 
HIV-infected persons to those without HIV, (2) com-
pare OS in HIV/TB co-infected individuals to those with 
HIV-mono infection and, (3) assess the association of  
ART with OS among hospitalized HIV and HIV/PTB 
co-infected patients in Uganda.
Methods
Study design and setting: We conducted a cross-sec-
tional study among consenting HIV-infected adults (≥18 
years) that were admitted to Mulago Hospital in Kampala, 
Uganda with possible pneumonia as part of  the Mulago 
Inpatient Non-invasive Diagnosis-International HIV-as-
sociated Opportunistic Pneumonias (MIND-IHOP) 
study18-21 from 2013-2015.
Inclusion criteria for the sub-study were: being HIV pos-
itive with or without TB disease, HIV positive with or 
without being on ART, HIV negative with no symptoms 
of  chronic disease(s) including TB, and availability of  suf-
ficient plasma and/or serum samples.
Exclusion criteria for the sub-study were: missing ART 
status related information, being on anti-tuberculosis 
therapy, age above 45 years, alcohol consumption (>10 
bottles for more than 4-times/week), and cigarette smok-
ing (>10 cigarettes/day).
We selected a convenience sample of  specimens from 
four HIV patient groups: (1) HIV-infected, ART-naïve, 
(2) HIV-infected, ART-treated, (3) HIV and PTB co-in-
fected, ART-naïve; and (4) HIV and PTB co-infected, 
ART-treated. ART naïve were newly diagnosed HIV 
patients who were not under formal HIV management 
until the time of  recruitment into the MIND-IHOP 
study.  HIV infection was confirmed at time of  enroll-
ment and PTB infection was diagnosed by direct fluo-
rescent microscopy (auramine-O staining) or GeneXpert 
MTB/RIF (Cepheid, Sunnyvale CA) with confirmation 
by Lowenstein-Jensen culture method. HIV was screened 
for using Abbott rapid diagnostic test (Abbott Japan Co 
ltd. Tokyo, Japan), and confirmed using a STAT-PAC test 
(Chembio diagnostic system, INC New York, USA). CD4 
counts were measured using a BD FACScalibur machine 
(BD Sciences, San Jose CA). We defined ART-treated pa-
tients as those who self-reported adherence to ART for 
≥6 months, while ART-naïve patients were HIV-infected 
patients who had never started ART. We additionally en-
rolled healthy controls testing negative for HIV, hepatitis 
B, and C and without TB symptoms at a local blood bank. 
To minimize confounders, we excluded cigarette smokers, 
alcohol drinkers, and persons who were above 45 years of  
age or who had already initiated TB treatment.
Oxidative stress (OS) assays: Stored serum (-200C) 
and plasma (-800C) were used. Selection of  markers was 
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based on their clinical significance, power to reflect OS, 
and feasibility of  their assays in our laboratory setting. OS 
is associated with elevated levels of  aspartate transami-
nase (AST), alanine transaminase (ALT), gamma glutamyl 
transaminase (GGT), total protein, and malondialdehyde 
(MDA). OS is also associated with decreased levels of  
serum albumin, vitamin C, and total anti-oxidant status 
(TAS).
We determined levels of  AST (U/L), ALT (U/L), GGT 
(U/L), and albumin (mg/ml) using a clinical chemistry 
automated analyzer (COBASR MIRA INTEGRA 400 
plus; Roche diagnostics, GMBH, Germany)22. This ana-
lyzer is located at the clinical chemistry laboratory of  Mu-
lago Hospital Complex, the National Referral Hospital in 
Kampala, Uganda.
Total protein levels were determined by Biuret method23. 
A mixture of  plasma, distilled water and Biuret reagent 
was homogenized and then incubated for 30 minutes at 
ambient temperature. Standard solution (2500µg/250ml 
albumin) was prepared in a similar way. Absorbances 
were read at 580nm. Total protein concentration was ob-
tained from a standard curve.
Plasma levels of  MDA (µM) were determined by a thio-
barbituric acid (TBA) method14. To 200µl of  plasma was 
added 100µl of  TBA (15g) /TBA (0.67g) /0.25MHCl 
(50ml) mixture, followed by 200µl 1M HCl. This mixture 
was heated at 950C for 1 hour, cooled on ice, and then 
centrifuged at 3000rpm for 2 minutes. The supernatant 
was mixed with 200µl of  3M NaOH and absorbance of  
the mixture was read (in duplicates) at 540nm within 10 
minutes. Concentration of  MDA (µM) was calculated us-
ing a factor (1.56x105 M-1cm).
Levels of  vitamin C (mg/dl) were determined by the acid 
phosphotungstate (PTA) method24. Equal volumes of  
plasma and color reagent (PTA) were incubated in the 
dark at ambient temperature for 30 minutes and then cen-
trifuged at 3000rpm for 15 minutes. Absorbance of  the 
supernatant was read at 700nm against a reagent blank. 
Vitamin C concentration was obtained from the standard 
curve constructed using standard ascorbic acid (99% 
ascorbic acid from BDH, laboratory supplies, Poole En-
gland).
Concentrations of  TAS were determined (in duplicates) 
by using a modified ABTS (RANDOX NX2332) meth-
od25. Briefly, 50µl of  the sample was mixed with 250µl of  
chromogen (R2). The mixture was incubated at 37oC for 
5 minutes before its absorbance (A1) was read at 600nm. 
To the mixture was then added 50µl of  chromogen (R3) 
and incubated at 370C for 3 minutes and its absorbance 
(A2) was read at 600nm. A reagent blank and standard 
were prepared in the same way but replacing the sample 
with double-distilled water and the standard, respectively. 
Difference in absorbance was calculated by subtracting 
A2 from A1 for all the three (blank, standard and sam-
ples). A factor was calculated by dividing the concentra-
tion of  the standard by difference in absorbance between 
the blank and the standard. Concentrations of  TAS were 
then calculated by multiplying the calculated factor with 
the difference in absorbance of  the blank and that of  the 
sample.
Statistical analysis: Statistical analysis was done using 
GraphPad Prism verion 4. We evaluated between-group 
differences using Mann-Whitney U test with an alpha lev-
el (p-value) of  0.05. We used one way ANOVA to com-
pare differencesin age and gender between more than 
two groups. Exposures evaluated as risk factors for OS 
included HIV, PTB, age, gender and ART status.
Results
Baseline characteristics
This study included 102 patients: 81 who were HIV-in-
fected and 21 who were HIV-negative healthy controls. 
Among the 81 HIV-infected, 21 were HIV-infected and 
ART-naïve, 14 were HIV-infected and ART-treated, 21 
were HIV and PTB co–infected and ART-naïve, and 25 
were HIV and PTB co-infected and ART-treated. The 
median age of  all study participants was 35 (IQR 28-42) 
years and 53% were women. Using One-way analysis 
of  variance (ANOVA) test, we did not identify a statis-
tically significant difference in gender (p=0.18) and age 
(p=0.41) across study groups. Among the HIV-infected 
patients, the median CD4 T-cell count was 110 (IQR 34-
234) cells/µl. The median time on ART was 17.5 months 
among the HIV-mono-infected patients and 11.0 months 
among the HIV and PTB co-infected patients. Among 
HIV-infected patients, there was a non-significant trend 
towards higher CD4 T cells counts among those who 
were ART-treated relative to those who were ART-naive 
(p=0.24) (Table 1).
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Oxidative stress  markers in HIV-infected patients 
and HIV-negative healthy controls
Consistent with increased OS in HIV, the 81 HIV-infect-
ed patients combined had higher median AST (U/L) [32.8 
vs 17.3; p<0.001], GGT (U/L) [64.0 vs 21.4; p<0.001], 
total protein (mg/ml) [42.9 vs 37.9; p=0.012], and MDA 
(µM) [1.73 vs 1.37; p<0.001] levels than the 21 HIV-nega-
tive controls. However, median ALT (U/L) level was low-
er in HIV-infected patients [9.0 vs 12.5; p=0.048]. Also 
consistent with OS, HIV-infected patients in all groups 
combined had significantly lower median levels of  albu-
min (g/l) [29 vs 44; p<0.001] and vitamin C (mg/dl) [0.17 
vs 0.51; p<0.001]. Although there was a trend towards 
lower median levels of  TAS (mmol/l) in the HIV-infect-
ed patients combined [1.6 vs 1.8; p=0.99], this was not 
statistically significant.
Association of  ART  with  oxidative stress markers 
in all HIV-infected patients
As hypothesized, albumin (g/l) was higher among the 
HIV-infected ART-treated compared to the HIV-infected 
ART-naïve patients [33.3 vs 27.5; p=0.001]. Median lev-
els of  AST, ALT, total protein, MDA, and TAS did not 
significantly (p>0.05) differ between the ART-treated and 
the ART-naïve patients. The ART-treated had higher me-
dian levels of  GGT (U/L) compared to the ART-naïve 
patients [77.0 vs 53.0; p = 0.023] and the median levels 
of  vitamin C (mg/dl) were significantly lower among the 
ART-treated compared to the ART-naïve patients [0.25 
vs 0.14; p=0.01] (Table 2).
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Table 1. Baseline demographic and clinical characteristics of the participants 
Abbreviations definitions: ART=Antiretroviral therapy, HIV=Human immune deficiency syndrome, 
TB=Tuberculosis. Results are presented as percent (n) or Median (Interquartile range: IQR).*p<0.001; all  in 
comparison with the referenc e group; N/A= not applicable 
Participant 
Characteristics 
HIV 
(ART naive) 
HIV 
(ART treated) 
HIV/PTB 
(ART naive) 
HIV/PTB 
(ART treated) 
Healthy 
Controls 
Number (n) 21 14 21 25 21 
Female gender (%) 9(43%) 8(57%) 15(71%) 11(46%) 11(55%) 
Age (years) Median(IQR) 31(22.5-39.0) 39.5(27.5-48.0) 32(27.5-37.5) 38(32.50-45.5)  30(27-33.0) 
CD4(cells/µl) Median(IQR) 87(26-247.5)* 112(21.5-265.5)* 82(23-152.5)* 165(76.5-165.5)* 870(708-1037)  
ART duration (months) Median (IQR) N/A 17.50(11-66)  N/A 11(9.50-36) N/A 
Table 1. Baseline demographic and clinical characteristics of the participants 
Abbreviations definitions: ART=Antiretroviral therapy, HIV=Human immune deficiency syndrome, 
TB=Tuberculosis. Results are presented as percent (n) or Median (Interquartile range: IQR).*p<0.001; all  in 
comparison with the referenc e group; N/A= not applicable 
Participant 
Characteristics 
HIV 
(ART naive) 
HIV 
(ART treated) 
HIV/PTB 
(ART naive) 
HIV/PTB 
(ART treated) 
Healthy 
Controls 
Number (n) 21 14 21 25 21 
Female gender (%) 9(43%) 8(57%) 15(71%) 11(46%) 11(55%) 
Age (years) Median(IQR) 31(22.5-39.0) 39.5(27.5-48.0) 32(27.5-37.5) 38(32.50-45.5)  30(27-33.0) 
CD4(cells/µl) Median(IQR) 87(26-247.5)* 112(21.5-265.5)* 82(23-152.5)* 165(76.5-165.5)* 870(708-1037)  
ART duration (months) Median (IQR) N/A 17.50(11-66)  N/A 11(9.50-36) N/A 
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(ART naive) 
HIV 
(ART treated) 
HIV/PTB 
(ART naive) 
HIV/PTB 
(ART treated) 
Healthy 
Controls 
Number (n) 21 14 21 25 21 
Fe al  gender (%) 9(43%) 8(57%) 15(7 %) 11(46%) 11(55%) 
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Association of  HIV mono-infection and HIV/PTB 
co-infection with oxidative stress markers
Median levels of  AST (U/L) [43.5 vs 28.2; p=0.03] and 
GGT (U/L) [75 vs 42; p=0.01] were significantly high-
er among the HIV and PTB co-infected when compared 
with the HIV mono-infected patients. However, median 
levels of  ALT, total protein, MDA, albumin, vitamin C, 
and TAS did not differ significantly (p>0.05) between the 
HIV and PTB co-infected and, the HIV-mono-infected 
patients (Table 3).
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Table 3. Oxidative stress markers in HIV mono-infected and HIV/TB co-infected patients 
Abbreviation: TP= Total protein, TAS=Total antioxidants status, MDA=Malondialdehyde, ALT=Alanine 
transaminase, AST= Aspartate transaminase, GGT=Gamma glutamyl transpeptidase. Legend: *All  patients 
combined regardless of their ART status 
Parameter HIV mono infected* HIV/PTB co-infected* P-value 
Vitamin C(mg/dl) Median(IQR) 0.16(0.11-0.35) 0.19(0.09-0.41) 0.76 
Albumin (g/l) Median(IQR) 28.2(19.0-34.45)  30.1(25.00-40.85) 0.14 
TP (mg/ml) Median(IQR) 42.9(39.45-46.90) 43.2(37.40-45.30) 0.78 
TAS (mmol/l) Median(IQR)  1.3(0.83-1.93) 1.7(1.12-2.37) 0.16 
MDA(µM) Median(IQR)   1.8(1.55-1.94) 1.7(1.54-1.87) 0.61 
ALT(IU) Median(IQR) 9.0(6.2-15.4)  9.1(5.45-13.90) 0.58 
AST(IU) Median(IQR) 28.2(20.65-42.20) 43.5(23.65-66.85) 0.03 
GGT(IU) Median(IQR) 42.0(22.5-66.00)  75.0(45-147)  0.01 
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transaminase, AST= Aspartate transaminase, GGT=Gamma glutamyl transpeptidase. Legend: *All  patients 
combined regardless of their ART status 
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Vitamin C(mg/dl) Median(IQR) 0.16(0.11-0.35) 0.19(0.09-0.41) 0.76 
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TP (mg/ml) Median(IQR) 42.9(39.45-46.90) 43.2(37.40-45.30) 0.78 
TAS (mmol/l) Median(IQR)  1.3(0.83-1.93) 1.7(1.12-2.37) 0.16 
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GGT(IU) Median(IQR) 42.0(22.5-66.00)  75.0(45-147)  0.01 
Table 3. Oxidative stress markers in HIV mono-infected and HIV/TB co-infected patients 
Abbreviation: TP= Total protein, TAS=Total antioxidants status, MDA=Malondialdehyde, ALT=Alanine 
transaminase, AST= Aspartate transaminase, GGT=Gamma glutamyl transpeptidase. Legend: *All  patients 
combined regardless of their ART status 
Parameter HIV mono infected* HIV/PTB co-infected* P-value 
Vitamin C(mg/dl) Median(IQR) 0.16(0.11-0.35) 0.19(0.09-0.41) 0.76 
Albu in (g/l) Median(IQR) 28.2(19.0-34.45)  30.1(25.00-40.85) 0.14 
TP (mg/ml) Median(IQR) 42.9(39.45-46.90) 43.2(37.4 - 5.30) .78 
TAS (mmol/l) Median(IQR)  1.3(0.83-1.93) 1.7(1.12-2.37) 0.16 
MDA(µM) Median(IQR)   1.8(1.55-1.94) . ( .54-1.8 ) .61 
ALT(IU) Median(IQR) 9.0(6.2-15.4)  9.1(5.45-13.90) .58 
ST(I ) e ia (I ) 28.2(20.65-42.20) 43.5(23.65-66.85) 0.03 
GGT(I ) edian(I R) 42.0(22.5-66.00)  75.0(45-147)  . 1 
Table 2. Oxidative stress markers among ART-treated versus ART naïve patients 
Abbreviations:TP= Total protein, TAS=Total antioxidant status, MDA=Malondialdehyde, ALT=Alanine transaminase, 
AST=Aspartate transaminase, GGT=Gamma glutamyl transpeptidase. Legend:*Includes both HIV-mono infected 
and HIV/TB co-infected patients 
Parameter 
 
HIV 
(ART-treated)* 
HIV 
(ART-naïve)* 
P-value 
(statistical power) 
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Association of  ART with  oxidative stress markers in 
HIV/PTB co-infected patients
Median vitamin C (mg/dl) level was lower among the 
ART-treated HIV and PTB co-infected relative to the 
ART-naïve HIV and PTB co-infected patients [0.14 vs. 
0.28; p=0.029]. However, median albumin (g/l) level was 
significantly higher [39.5 vs 25.5; p<0.001] among the 
ART-treated HIV and PTB co-infected patients relative 
to the ART-naïve HIV and PTB co-infected patients. 
Median levels of  AST, ALT, GGT, total protein, MDA, 
and TAS did not differ significantly (p>0.05) between the 
ART-treated HIV and PTB co-infected, and the ART-
naïve HIV and the PTB co-infected patients. (Table 4).
Discussion
In this study of  hospitalized HIV and HIV/PTB co-in-
fected patients in Uganda, we found that HIV-infected 
patients were under severe OS with both increased lev-
els of  OS markers and decreased levels of  anti-oxidants. 
Overall, neither ART nor PTB were associated with a sig-
nificant difference in levels of  OS markers. This suggests 
that anti-oxidant supplementation might be beneficial ir-
respective of  ART use.
As a group, HIV-infected patients had lower levels of  
plasma vitamin C and albumin and higher MDA rela-
tive to healthy controls, consistent with higher oxidative 
stress. Vitamin C scavenges free radicals and may be de-
pleted due to increased free radical production in HIV/
PTB26-28. HIV proteins such as negative regulatory factor 
(Nef), Viral protein r(Vpr) and trans-activator of  tran-
scription (Tat) act as direct modulators of  OS through 
up-regulating free radicals production and invasion of  
the antioxidant defense system29. MTB increases levels of  
free radicals through activation of  the membrane bound 
NADPH oxidase and myeloperoxidase enzymes leading 
to respiratory burst. Additionally, the low levels of  plas-
ma vitamin C among the HIV and HIV/PTB co-infected 
patients may be explained by low dietary intake or malab-
sorption due to oxidative damage on the gastrointestinal 
tract30. Our findings are consistent with previous reports 
of  low plasma vitamin C and serum albumin levels in am-
bulatory HIV and PTB-infected individuals31-36. Impor-
tantly, low levels of  vitamin C is a risk factor to certain 
cancers and scurvy37, while low serum albumin levels in-
dependently predict in-hospital death38,39. MDA is a prod-
uct of  lipid peroxidation that is caused by the free radi-
cals attack on the polyunsaturated fatty acids in the cell 
membranes14. Higher levels of  MDA in HIV and HIV/
PTB co-infected patients may hence indicate increased 
production of  ROS molecules. MDA is transported by 
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lipoproteins to distant tissues by circulation. There, MDA 
induces secondary production of  ROS and subsequent 
uncontrolled lipid peroxidation. Over production of  
MDA through uncontrolled lipid peroxidation may cause 
systemic cell damage through altering the cell membrane 
fluidity. This may further compromise the immune sys-
tem and lead to poor health of  the HIV and HIV/PTB 
co-infected patients40-43.
Different populations on ART may have different OS 
levels due to differences in their lifestyle, environment 
pollutants and genetic variability. Conceptually, ART 
could reduce OS by reducing viral activity. However, ART 
drugs and/or their metabolic products may also augment 
OS by blocking the anti-oxidant-defense system44, or by 
activating the pathways that produce free radicals. Be-
chan Sharma proposed that ART or its metabolites could 
block three key anti-oxidant enzymes including superox-
ide dismutase, glutathione peroxidase, and glutathione 
reductase. Subsequently, this would lead to accumulation 
of  ROS molecules such as superoxide anions, hydrogen 
peroxides44.
Several previous studies have had conflicting findings 
regarding the association of  ART with OS. Among am-
bulatory HIV patients in Nigeria, ART reduced OS14. 
However, other studies showed that ART augments OS45-
51. Enhanced OS during ART treatment may be due to 
altered oxidative phosphorylation and increased produc-
tion of  oxidized metabolites. Interestingly, the magnitude 
of  ART induced OS seems to be differential and depen-
dent on a number of  factors including ART duration and 
adherence, and the composition of  the therapeutic regi-
men52-54. In the current study, we did not identify a signifi-
cant association between ART and most of  the OS mark-
ers, but we also did not have sufficient power to examine 
the impact of  specific ART medications or ART duration 
on OS. This observation suggests that all HIV-infected 
patients, regardless of  ART use, could potentially benefit 
from extrinsic anti-oxidant supplementation.
Hepatic markers reflect OS and end organ dysfunction 
although they are not yet regarded as cardinal markers of  
OS. GGT, total protein and liver transaminases (ALT and 
AST) have been suggested as inexpensive and easily as-
sayed markers of  OS in humans55 and in animal56 models.
In this study, we observed higher levels of  GGT, AST 
and total protein among HIV and HIV/PTB co-infected 
patients, which is consistent with increased OS regardless 
of  the ART status. Being on ART was associated with 
significantly higher GGT among the HIV mono-infect-
ed but this was not the case among the PTB co-infect-
ed patients. The reason for this disparity was unclear to 
us. However, it could partly be attributed to ART dura-
tion. ART duration among the HIV-mono-infected was 
6 months higher than that among the PTB co-infected 
patients. OS due to HIV and PTB infections or to chron-
ic ART use may independently be associated with inflam-
matory reactions which may cause increased production 
of  proteins mainly the globulins49, and oxidative liver tis-
sue damage. This could explain the higher levels of  GGT, 
AST and total protein that we observed in the HIV and 
HIV/PTB co-infected patients.
This study has several limitations. Since this was a cross 
sectional study, we could not confirm OS causality. Our 
sample size of  HIV mono-infected patients was small, 
potentially limiting our power to identify small effects. 
ART adherence was based on the patients’ self-report, 
and may tend to over-estimate exposure. We were unable 
to assess the impact of  variation in bacillary load and se-
verity of  TB disease. Some of  the cardinal makers of  OS 
such as glutathione, superoxide dismutase, and catalase, 
were not assessed. Nevertheless, our study provides im-
portant new insights into OS in HIV and HIV/TB co-in-
fected patients in sub-Saharan Africa.
Conclusion
This study has demonstrated severe OS among hospi-
talized HIV-patients compared with those without HIV. 
We have shown that markers of  OS do not significantly 
differ between HIV/PTB co-infected persons compared 
with those who were HIV mono-infected. We have also 
demonstrated that markers of  OS do not significantly dif-
fer between ART treated persons and those who are ART 
naïve.
We hence recommend studies to explore the potential 
benefit of  intervention with cost effective anti-oxidants 
supplementation in HIV patients.
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